Clazakizumab
- Generic Name
- Clazakizumab
- Brand Names
- -
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 1236278-28-6
- Unique Ingredient Identifier
- 4S38Z8RA9O
- Background
Clazakizumab has been used in trials studying the treatment of Rheumatoid Arthritis.
- Associated Conditions
- -
- Associated Therapies
- -
Improving Physical Function in Older Adults Using an Anti-inflammation Drug: the RIGHT Study
- First Posted Date
- 2023-02-14
- Last Posted Date
- 2024-12-16
- Lead Sponsor
- Anne B. Newman
- Target Recruit Count
- 60
- Registration Number
- NCT05727384
- Locations
- πΊπΈ
University of Pittsburgh, Health Studies Research Center, Pittsburgh, Pennsylvania, United States
Clazakizumab vs. Placebo - COVID-19 Infection
- First Posted Date
- 2020-07-31
- Last Posted Date
- 2020-07-31
- Lead Sponsor
- The Methodist Hospital Research Institute
- Target Recruit Count
- 60
- Registration Number
- NCT04494724
- Locations
- πΊπΈ
Houston Methodist Hospital, Houston, Texas, United States
Study for the Use of the IL-6 Inhibitor Clazakizumab in Patients With Life-threatening COVID-19 Infection
- First Posted Date
- 2020-05-08
- Last Posted Date
- 2022-04-08
- Lead Sponsor
- Columbia University
- Target Recruit Count
- 1
- Registration Number
- NCT04381052
- Locations
- πΊπΈ
Columbia University Medical Center / New York Presbyerian Hospital, New York, New York, United States
Clazakizumab (Anti-Interleukin 6 (IL-6) Monoclonal) Compared to Placebo for Coronavirus Disease 2019 (COVID-19)
- First Posted Date
- 2020-04-16
- Last Posted Date
- 2024-02-08
- Lead Sponsor
- Cedars-Sinai Medical Center
- Target Recruit Count
- 17
- Registration Number
- NCT04348500
- Locations
- πΊπΈ
Cedars-Sinai Medical Center, Los Angeles, California, United States
PrecISE (Precision Interventions for Severe and/or Exacerbation-Prone Asthma) Network Study
- Conditions
- Interventions
- First Posted Date
- 2019-10-17
- Last Posted Date
- 2024-07-11
- Lead Sponsor
- University of North Carolina, Chapel Hill
- Target Recruit Count
- 395
- Registration Number
- NCT04129931
- Locations
- πΊπΈ
Cleveland Clinic, Cleveland, Ohio, United States
πΊπΈUniversity of California San Diego: Airway Research & Clinical Trials Center, San Diego, California, United States
πΊπΈUniversity of California San Francisco, San Francisco, California, United States
Clazakizumab for Chronic and Active Antibody Mediated Rejection Post-Kidney Transplant
- First Posted Date
- 2017-12-21
- Last Posted Date
- 2024-05-17
- Lead Sponsor
- Stanley Jordan, MD
- Target Recruit Count
- 10
- Registration Number
- NCT03380377
- Locations
- πΊπΈ
Norko Ammerman, Los Angeles, California, United States
Clazakizumab in Highly-HLA Sensitized Patients Awaiting Renal Transplant
- First Posted Date
- 2017-12-21
- Last Posted Date
- 2024-03-13
- Lead Sponsor
- Stanley Jordan, MD
- Target Recruit Count
- 20
- Registration Number
- NCT03380962
- Locations
- πΊπΈ
Norko Ammerman, Los Angeles, California, United States
Phase IIB Dose Ranging Study in Subjects With Moderate to Severe Rheumatoid Arthritis
- Conditions
- Interventions
- First Posted Date
- 2013-12-19
- Last Posted Date
- 2021-05-12
- Lead Sponsor
- CSL Behring
- Target Recruit Count
- 143
- Registration Number
- NCT02015520
- Locations
- πΊπΈ
Cincinnati Rheumatic Disease Study Group, Cincinnati, Ohio, United States
πΊπΈSeattle Rheumatology Associates, Seattle, Washington, United States
πΊπΈCenter For Inflammatory Disease, Nashville, Tennessee, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.